Company profile
Evariste company profile
Evariste advances synthetic lethal oncology using its AI-enabled platform, Frobenius. The company uses its platform to identify novel synthetic lethal targets and biomarkers, and then addresses them by developing small molecule therapeutic drug candidates. Frobenius has been validated through several external partnerships and Evariste's own internal pipeline, which includes a best-in-class PKMYT1 inhibitor program and several first-in-class assets aimed at novel targets
Business identity
- Website
- https://www.evariste.com/
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0-$1M
- Founded
- 2017-01-01, Year
Headquarters
- Headquarters
- Newdigate, England, United Kingdom
- Country code
- GB
- Continent
- Europe